Atara Secures FDA Resubmission Path for Tabelecleucel BLA, Preserves Review Timeline
Atara Biotherapeutics said it will resubmit its Biologics License Application for tabelecleucel after receiving an FDA complete response letter, preserving its regulatory review timeline. The company confirmed it will provide additional manufacturing and clinical data to address FDA feedback and maintain its planned PDUFA target in early 2027.
1. Regulatory Resubmission Plan
Atara Biotherapeutics outlined its path to resubmit the BLA for tabelecleucel following FDA feedback on manufacturing and clinical data. The company plans to compile additional documentation on CMC processes and trial endpoints to uphold its projected review timeline and PDUFA target in early 2027.
Related News
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
CNS
Cohen & Steers Partners with J.P. Morgan on Short-Duration Hybrid Credit Fund Expansion
CNS•
NVDA
Nvidia Cuts China From Outlook, Highlights $1 Trillion Hyperscaler Capex Forecast
NVDA•
GOOGL
Google and Blackstone Form $5B AI Cloud JV for 500MW Capacity by 2027
GOOGL•
MMYT
MakeMyTrip Q4 Cash Hits $782M with 1.82% Margin and 15.2% Accommodation Growth
MMYT•
Sources
BF